Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kees Brinkman

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|August 12, 2009
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I productionRemco Franssen, Raaj R Sankatsing, Elly Hassink, et al.
Open Forum Infectious Diseases|July 5, 2022
Ethnic Differences in Coronavirus Disease 2019 Hospitalization and Hospital Outcomes in a Multiethnic Population in the NetherlandsDidier Collard, Karien Stronks, Vanessa Harris, et al.
BMC Infectious Diseases|June 3, 2021
Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional studySaskia J Bogers, Maarten F Schim van der Loeff, Udi Davidovich, et al.
Plos Medicine|April 6, 2012
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trialMarlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 14, 2023
Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost SavingsVincent R Lanting, Piter Oosterhof, Daoud Ait Moha, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 28, 2018
SNP rs688 within the low-density lipoprotein receptor (LDL-R) gene associates with HCV susceptibilityGaby S Steba, Sylvie M Koekkoek, Michael W T Tanck, et al.
Virology|July 1, 2005
Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virusNico Kloosterboer, Paul H P Groeneveld, Christine A Jansen, et al.
Viral Immunology|December 15, 2010
Immunological analysis of treatment interruption after early highly active antiretroviral therapyIngrid M M Schellens, Katalin Pogany, Geertje H A Westerlaken, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2007
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)Katalin Pogány, Irene G M van Valkengoed, Irene G Vanvalkengoed, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Arteriosclerosis, Thrombosis, and Vascular Biology|August 12, 2009
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I productionRemco Franssen, Raaj R Sankatsing, Elly Hassink, et al.
Open Forum Infectious Diseases|July 5, 2022
Ethnic Differences in Coronavirus Disease 2019 Hospitalization and Hospital Outcomes in a Multiethnic Population in the NetherlandsDidier Collard, Karien Stronks, Vanessa Harris, et al.
BMC Infectious Diseases|June 3, 2021
Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional studySaskia J Bogers, Maarten F Schim van der Loeff, Udi Davidovich, et al.
Plos Medicine|April 6, 2012
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trialMarlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 14, 2023
Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost SavingsVincent R Lanting, Piter Oosterhof, Daoud Ait Moha, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 28, 2018
SNP rs688 within the low-density lipoprotein receptor (LDL-R) gene associates with HCV susceptibilityGaby S Steba, Sylvie M Koekkoek, Michael W T Tanck, et al.
Virology|July 1, 2005
Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virusNico Kloosterboer, Paul H P Groeneveld, Christine A Jansen, et al.
Viral Immunology|December 15, 2010
Immunological analysis of treatment interruption after early highly active antiretroviral therapyIngrid M M Schellens, Katalin Pogany, Geertje H A Westerlaken, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2007
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)Katalin Pogány, Irene G M van Valkengoed, Irene G Vanvalkengoed, et al.
Pageof 10